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Streszczenie
Rola gastryny i jej receptorów w rozwoju raka jelita 
grubego jest od dawna postulowana, lecz nadal pozostaje 
nie w pełni wyjaśniona. Z kolei skuteczność terapeutyczna 
fluorouracylu (FU), leku z wyboru w zaawansowanych 
postaciach raka jelita grubego, jest niewystarczająca, 
dlatego trwają poszukiwania czynników nasilających 
przeciwnowotworowe działanie FU. Ostatnio w naszym 
laboratorium wykazaliśmy synergistyczne działanie 
proglumidu, nieselektywnego blokera receptorów 
cholecystokininowo-gastrynowych, z FU w zahamowaniu 
proliferacji i nasileniu apoptozy w raku jelita grubego 
Colon 38 zaindukowanym u myszy in vivo.
Celem pracy było zbadanie bezpośredniego wpływu 
proglumidu (10-5-10-10 M) stosowanego osobno lub łącznie 
z FU (25, 2,5 i 0,25 µg/ml) na proliferację komórek 
mysiego raka jelita grubego Colon 38 in vitro. Proliferację 
komórkową oznaczano w oparciu o zmodyfikowaną 
metodę kolorymetryczną Mosmanna.
Proglumid zastosowany osobno hamował proliferację 
komórkową w stężeniach 10-6, 10-8, 10-10 M. FU we 
wszystkich badanych stężeniach hamował proliferację 
komórek linii Colon 38 w porównaniu z grupą kontrolną, 
wykazując najsilniejsze działanie w stężeniach 2,5 i 25 
µg/ml. Hamujące działanie FU w stężeniu 2,5 µg/ml 
okazało się nieznacznie silniejsze niż efekt 10-krotnie 
wyższego stężenia FU, dlatego do badań jego interakcji 
z proglumidem wybrano stężenie 2,5 µg/ml. Proglumid 
zastosowany łącznie z FU wykazywał synergistyczne 
działanie w zahamowaniu proliferacji komórkowej 
Colon 38 w stężeniach 10-8, 10-9 i 10-10 M. Najsilniejszy 
efekt hamujący proliferację obserwowano w grupie 
inkubowanej z FU (2,5 µg/ml) i proglumidem 10-10 M. 
Uzyskane wyniki wskazują na możliwość opracowania 
nowych schematów leczniczych w raku jelita grubego, 
co wymaga dalszych badań sprawdzających czy 
synergistyczne działanie FU z proglumidem występuje 
również w ludzkich rakach jelita grubego.
(Endokrynol Pol 2005; 6(56): 933-938)
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Abstract
The role of gastrins and their receptors in the pathogenesis 
of colon cancer has been discussed for many years but it 
still remains unresolved. Although fluorouracil (FU) 
remains to be reference chemotherapy for colon cancer, 
its efficacy is unsatisfactory. Recently, we have shown a 
synergistic effect of proglumide (a non-selective blocker of 
cholecystokinin-gastrin receptors) applied together with 
FU, on the proliferation and apoptosis of transplantable 
Colon 38 cancer cells in vivo. 
The aim of this study was to examine direct effects of 
proglumide (10-5-10-10 M) applied either alone or together 
with FU (0.25, 2.5 and 25 µg/ml) on the proliferation of 
murine Colon 38 cancer cells in vitro. Cell proliferation 
was assessed by the modified colorimetric Mosmann 
method.
Proglumide inhibited the proliferation of Colon 
38 cells at the concentrations of 10-6, 10-8 and 10-10 M. 
FU inhibited the proliferation of cancer cells in all 
studied concentrations, exerting the most profound 
antiproliferative effect at the concentrations of 2.5 and 
25 µg/ml. Thus, the former concentration was chosen 
to study its interactions with proglumide. Proglumide 
applied together with FU exerted a synergistic effect on 
the inhibition of proliferation of Colon 38 cells at 10-8, 
10–9, 10-10 M concentrations. The most profound inhibitory 
effect was observed in the group incubated with FU and 
10-10 M of proglumide. 
The obtained results indicate a possibility of new 
therapeutic options for colon cancer, but further studies 
are needed to elucidate, if the synergistic effect of FU and 
proglumide occurs also in the colon cancer in humans.
(Pol J Endocrinol 2005; 6(56): 933-938)
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Introduction
Colon cancer is a growing medical problem, 
especially in industrialized countries, where its 
incidence has increased systematically since the 
1970s [1, 2]. Colon cancer is often diagnosed late, 
in advanced stages of the disease, when it is lethal. 
Until the mid-1990s, fluorouracil (FU) was the 
primary and the only chemotherapeutic agent, 
available for the treatment of advanced-stages 
of local and metastatic colorectal cancers, but 
its efficacy is unsatisfactory [3]. During the last 
decade, five new drugs have been approved for 
treatment of metastatic colorectal cancer. Three 
of them are cytostatic agents: irinotecan, oxali-
platin and capecitabine, and two of them include 
non-cytotoxic monoclonal antibodies (approved 
by FDA in 2004), targeting VEGF (bevacizumab) 
and EGF receptor (cetuximab) [4]. Despite these 
new possibilities, colorectal cancer treatment still 
remains only palliative with no proofs for any 
increase of cure rates. These a.m. non-cytotoxic 
agents demonstrate a significant antitumor activity 
in patients with advanced colon cancer, either alone 
(cetuximab in patients with EGF-R positive and 
irinotecan-refrectory tumors) or in combination 
with cytotoxic drugs [5, 6]. Moreover, an addition 
of one of these non-cytotoxic agents to fluoroura-
cil- or irinotecan-based chemotherapy improves the 
survival among patients with metastatic cancer [5, 
6]. The observed clinical advantages of these new 
non-cytotoxic drugs over traditional chemotherapy 
allow expecting these targeted drugs to become 
gold means and standard therapies for colorectal 
cancer within a short period of time [4].
Another target in colorectal cancer seems to 
be gastrin receptors. The role of gastrins and their 
receptors in the development of colon cancer has 
been postulated for several years but it still remains 
uncertain. It has been shown that: gastrin levels are 
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higher in patients with colon cancer than in normal 
people [7]; the presence of gastrin, its precursor, 
gastrin mRNA and gastrin-cholecystokin receptors 
B in colon cancer tissues have been found [8, 9, 
10], however, opposite results also exist [11, 12]. 
Moreover, trophic effects of gastrin or pentaga-
strin (gastrin analog) [13, 14] and antiprolifera-
tive and/or proapoptotic effects of proglumide (a 
non-specific antagonist of gastrin/cholecystokinin 
receptors) [13, 15, 16] have been demonstrated 
on colon cancer growth but there have also been 
contradictory reports [12]. Are gastrins to be 
regarded as promoters of colorectal cancer? But 
the recent data speak in favor of this conception. 
In a large prospective case-control study (among 
128,992 subscribers), published in 1998 [17], the 
authors concluded that hypergastrinemia was 
associated with an increased risk of colon cancer 
in about 9% of cases. Moreover, in the recent years, 
the hypothesis, concerning the role of gastrins in 
colon carcinogenesis, has changed on the basis of 
the results from transgenic animals, either lacking 
or overexpressing various forms of gastrins [18, 19, 
20]. Most of recent studies have shown that neither 
matured form of gastrin (amidated gastrin) nor 
classical gastrin /CCK-B receptors are involved in 
colon carcinogenesis, but its less processed forms 
(glycine-extended gastrin and progastrin) and 
putative gastrin-glycine receptors seem to be the 
major players. In the excellently designed study, 
glycine-extended gastrin (G-Gly), but not matured 
gastrin, increased the invasiveness of colon cancer 
cells, what was inhibited via non-selective gastrin/
CCK receptor antagonists (proglumide and benzo-
tript), but not via specific gastrin/CCK-B antagonist 
(YM022) [21]. The other authors found that trans-
genic mice with pharmacologic levels of progastrin 
exhibited increased susceptibility to colon carcino-
genesis in response to carcinogen (azoxymethane) 
[18, 20], whereas gastrin knockout mice were also 
more susceptible to carcinogen than the wild-type 
mice [19]. These data suggest even a protective role 
of amidated gastrin in colon carcinogenesis and a 
potent co-carcinogenic role of its less processed 
forms, termed nonamidated gastrins (progastrin 
and glycine-extended gastrin). In the light of these 
data, the earlier discrepancies in the literature, 
concerning the role of gastrins in colon carcinogene-
sis, seem to be understandable. 
Recently, in our laboratories, two separate experi-
ments were performed (short and long lasting) with 
pentagastrin and proglumide (effective in inhibiting 
action evoked via putative G-Gly receptors), given 
either separately or together with FU on the growth 
of the transplantable Colon 38 cancer in mice. We 
found that proglumide alone induced apoptosis 
of tumor cells, in both the short- and the long-
term studies and, administered jointly with FU, it 
evoked even a synergistic effect on the inhibition of 
cell proliferation and induction of apoptosis in the 
long term study [13, 16]. Those data suggest both 
direct or indirect effects of proglumide on Colon 38 
cancer.
Thus, the aim of the present study was to 
examine the direct effects of proglumide at various 
concentrations, applied either alone or together 
with FU, on the proliferation of murine Colon 38 
cancer cells in vitro.
Material and methods
Murine Colon 38 cancer cells were used in the 
study. The cells were cultured in a culture flask 
(Nunc Eas Y flask 25cm2, NUNC) in the presence of 
RPMI 1640 medium (Sigma), supplemented with: 
25 mM Hepes buffer (Sigma), 4 mM L-glutamine 
(Sigma), 100 U/ml penicillin and 100 µg/ml strep-
tomycin solution (Sigma), 2g/l sodium bicarbonate 
(Sigma) and 5% fetal calf serum (FCS, Biochrom) 
(complete medium). The cells were routinely 
cultured in a humidified incubator at 37oC with 
5% carbon dioxide. Before confluency, the cells 
were harvested every 3-4 days in the presence of 
preheated (37oC) trypsin-EDTA at concentration of 
0.05 and 0.02% respectively, in Hanks-balanced salt 
solution (Trypsin-EDTA, Sigma). Thereafter, the 
cells were collected, rinsed three times in culture 
medium, centrifuged and seeded in culture flask 
(2x105 cells/5 ml medium) for subsequent 4 days. 
After one of the following trypsinization procedures 
the cells were suspended in complete medium in 
amount of 4x105 cells/ml. Fifty µl aliquots of this 
suspension (20x103 cells) was seeded into each well 
of the culture plate (96 Cell Culture Cluster Dish, 
Nunclon MicroWell Plates, NUNC) and preincu-
bated for 24 hours. Then, the cells were cultured for 
further 24 hours in the presence of various concen-
trations of the examined substances (fluorouracil 
and proglumide) applied either alone or jointly. 
Three separate cultures were performed. In culture 
I the effects of fluorouracil (FU, Fluoro-uracil, 
Roche) were examined at concentrations of 25, 2.5 
and 0.25 µg/ml; the control groups were incubated 
in complete medium only. In culture II, the effects 
of various concentrations of proglumide (P, Proglu-
mide, Sigma) (10-5, 10-6, 10-7 and 10-8M) were investi-
gated; the control groups were cultured in presence 
of proglumide solvent (ethanol with complete 
medium; ethanol concentration was 6.6x10-3 vol% 
as in the wells with the highest concentrations of 
proglumide). In culture III the effects of various 
concentrations of proglumide (10-8, 10-9 i 10-10M), 
applied either alone or together with fluorouracil, 
at the concentration of 2.5 µg/ml, were studied; the 
control groups for fluorouracil (Cm) were cultured 
in presence of complete medium only, for proglu-
mide (Ce) in the presence of complete medium with 
ethanol (ethanol concentration 7.4x10-6vol%). The 
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cell proliferation was assessed by the colorime-
tric Mosmann method, using the EZ4Y kit (Easy 
for You, The 4th Generation Non Radioactive 
Cell Proliferation & Cytotoxity Assay, Biomedica 
Gruppe, Austria, Bellco Biomedica Poland). This 
method is based on the transformation of tetra-
zolium salt into coloured soluble formazan via 
mitochondrial enzymes, what correlates well with 
cell proliferation and viability. The intensity of 
reaction was estimated via measurement of optical 
density (OD), using an ELISA reader (λ=450nm). 
The data were statistically analyzed by ANOVA 
and the significance of differences between means 
was determined by LSD (Least Significant Diffe-
rences). P<0.05 was considered as the borderline of 
statistic significance.
Results
The obtained results are present on Figures 1-3. 
We designed culture I as having the most effective 
antiproliferative concentration of fluorouracil (FU) 
on Colon 38 cancer cells in vitro. We found that all 
the examined concentrations of FU inhibited the 
proliferation of Colon 38 cancer cells (Fig. 1). The 
most profound antiproliferative effect of FU was 
obtained in the following two concentrations: 2.5 
and 25 µg/ml. The inhibitory effect of FU, at the 
concentration of 2.5 µg/ml, was slightly stronger 
than the effect of a 10 times higher concentration of 
FU (25 µg/ml), thus we chose the former concen-
tration to study the interaction between FU and 
proglumide. Proglumide, applied alone, inhibited 
the proliferation of Colon 38 cells at the concentra-
tions of 10-6, 10-8 and 10-10 M (Fig. 2, 3). The other 
examined concentrations of proglumide (10–5, 10 
–7, 10-9 M) were insufficient in inhibiting Colon 38 
cancer cell proliferation effectively. Proglumide, 
applied together with FU (2.5 µg/ml), exerted a 
synergistic effect (stronger than the effect of FU or 
proglumide applied alone) on the inhibition of cell 
proliferation of Colon 38 cancer in all the examined 
concentrations (10-8, 10-9, 10-10 M) (Fig. 3). Even at the 
concentration of 10-9 M, which was ineffective in the 
inhibition of cell proliferation, proglumide, applied 
together with FU, enhanced the antiproliferogenic 
effect of the latter. The most profound inhibitory 
effect was observed in the group incubated in the 
presence of FU (2.5 µg/ml) and proglumide at the 
lowest of the examined concentrations, e.g., 10-10 M 
(Fig. 3). 
Discussion
The data, obtained by us, indicate that proglumide 
caused a slight but statistically significant, direct 
inhibitory effect on the proliferationof Colon 38 
cancer. In this study, proglumide, applied alone, 
inhibited cell growth of Colon 38 cancer in vitro at 
Fig. 1
The effects of various concentrations of fluorouracil (FU, 0.25; 2.5 and 25 g/ml) on the proliferation of Colon 38 cancer cells.
C- control, OD-optical density, X±SEM, *P<0.001 vs C.
Fig. 2.
The effects of various concentrations of proglumide (P) on the proliferation of Colon 38 cancer cells.
C-control, OD-optical density, X±SEM, *P<0.001 vs C, **P<0.01 vs C.
Fig. 3.
The effect of proglumide (P), 5-fluorouracil (FU) and combination of proglumide and 5-fluorouracil in concentration of 2.5 g/ml
on the proliferation of Colon 38 cancer cells.
Cm-control for fluorouracil (with complete medium only), Ce-control forproglumide (complete medium with ethanol), OD-optical density, X±SEM,
*P<0.001 vs Cm, **P<0.05 vs Ce, ***P<0.001 vs Cm and Ce, ^P<0.05 vs FU-2.5, ^^P<0.001 vs FU-2.5,
#P<0.001 vs P-8, ##P<0.001 vs P-9,
###P<0.001 vs P-10, +P<0.01 vs P-8FU and vs P-9FU.
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Fig. 1. Effects of various concentrations of fluorouracil 
(FU, 0.25; 2.5 and 25 µg/ml) on the proliferation of Colon 
38 cancer cells. C- control, OD-optical density, X±SEM, 
*P<0.001 vs C.
Ryc. 1. Wpływ różnych stężeń 5-fluorouracylu (FU; 0,25; 
2,5 and 25 µg/ml) na proliferację komórkową linii Colon 
38. C- kontrola, OD-optical density, X±SEM, *P<0,001 
vs C.
Fig. 2. Effects of various concentrations of proglumide (P) 
on the proliferation of Colon 38 cancer cells. C-control, 
OD-optical density, X±SEM, *P<0.001 vs C, **P<0.01 
vs C.
Ryc. 2. Wpływ różnych stężeń proglumidu (P) na 
proliferację komórkową linii Colon 38. C-kontrola, OD-
optical density, X±SEM, *P<0.001 vs C, **P<0.01 vs C.
Fig. 1
The effects of various concentrations of fluorouracil (FU, 0.25; 2.5 and 25 g/ml) on the proliferation of Colon 38 cancer cells.
C- control, OD-optical density, X±SEM, *P<0.001 vs C.
Fig. 2.
The effects of various concentrations of proglumide (P) on the proliferation of Colon 38 cancer cells.
C-control, OD-optical density, X±SEM, *P<0.001 vs C, **P<0.01 vs C.
Fig. 3.
The effect of proglumide (P), 5-fluorouracil (FU) and combination of proglumide and 5-fluorouracil in concentration of 2.5 g/ml
on the proliferation of Colon 38 cancer cells.
Cm-control for fluorouracil (with complete medium only), Ce-control forproglumide (complete medium with ethanol), OD-optical density, X±SEM,
*P<0.001 vs Cm, **P<0.05 vs Ce, ***P<0.001 vs Cm and Ce, ^P<0.05 vs FU-2.5, ^^P<0.001 vs FU-2.5,
#P<0.001 vs P-8, ##P<0.001 vs P-9,
###P<0.001 vs P-10, +P<0.01 vs P-8FU and vs P-9FU.
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the concentration of 10-6, 10-8, 10-10 M, but it did not 
change the proliferation at other examined concen-
trations, such as: 10-5, 10-7, 10-9 M. The explanation 
of these divergent effects of the changed concentra-
tions of proglumide might be connected with the 
existence of three receptor subtypes, which mediates 
the effect of this drug on Colon 38 cancer cells. This 
speculatio  is based on the fact that proglumide, the 
non-selective antagonist of gastrin/CCK receptors 
(existing in two classical subtypes: gastrin/CCK-A 
and B receptors, presently called CCK1 and CCK2 
respectively), seems to block also the putative 
gastrin-Gly (G-Gly) receptors, through which the 
less processed forms of gastrin exert their growth 
effect [21]. Another explanation of this changing 
(fluctuating) effect of proglumide may depend on 
the too short period of time of the culture; it lasted 
only 24 hours. Perhaps, the culture should have 
lasted much longer to observe full inhibitory effects 
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of proglumide. On the basis of the obtained data, 
we hypothesize that a direct antiproliferative effect 
of proglumide on Colon 38 cancer cells is caused via 
the interruption of postulated autocrine loop, consi-
sting of nonamidated gastrins (probably secreted 
by the examined Colon 38 cancer cells) and their 
putative gastrin-Gly receptors. 
The antiproliferogenic effect of proglumide, 
found in this study, is in accordance with our own 
data showing proapoptotic effect of proglumide 
on Colon 38 cancer cells in vivo, in both the short-
term and the long-term study [13, 16]. It is worth 
recalling, that the Mosmann method, used in the 
present study, measures the metabolic status of the 
cells, which positively correlates with the number of 
proliferating cells and negatively with the number 
of apoptotic cells. Our results are also compatible 
with the data obtained by other authors, who have 
showed that proglumide inhibits the growth of 
colon cancer cells, both in vivo and in vitro and 
enhances survival in tumor-bearing mice [15, 22]. 
Despite these encouraging data concerning the 
beneficial effects of proglumide on colon cancer 
growth and the survival of animals, the chances 
of the possible use of this drug (introduced into 
routine medical practice) in the treatment of colon 
cancer patients have not been evaluated, since some 
reports show that matured forms of gastrin are not 
involved in colorectal carcinogenesis [23, 24]. It has 
been postulated that neither amidated gastrin nor 
classical gastrin/CCK receptors are involved in 
colorectal carcinogenesis. The problem seems to 
be even more complicated because other authors 
have suggested that colon cancers, originating from 
different part of the colon, seem to have different 
pathogenesis [25]. 
Since proglumide has been shown to inhibit 
a proliferogenic action of nonamidated (interme-
diate, less processed) forms of gastrins on colon 
cancer cells via blocking the putative gastrin-Gly 
receptors, the renaissance of this drug starts again 
in the study, concerning colon cancer [21].
In the present study, we checked also combined 
effects of FU and proglumide on the growth of 
Colon 38 cancer cells. We found that proglumide in 
all the examined concentrations, applied jointly with 
FU, evoked a synergistic antiproliferogenic effect 
on Colon 38 cancer cells. This beneficial combined 
effect of proglumide and FU remains in accordance 
with our own data, showing that these two drugs 
caused the strongest antiproliferative and proapop-
totic effect on Colon 38 cancer, transplantable in 
mice, in comparison to the effect, evoked by each of 
these substances, when given separately [13].
On the basis of these findings, we hypothesize 
that a combined administration of FU and proglu-
mide in the treatment of colon cancer patients 
would improve the effectiveness of FU-based 
chemotherapy. Further studies are needed to 
elucidate whether this suggestion is worth clinical 
applications.
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The effects of various concentrations of fluorouracil (FU, 0.25; 2.5 and 25 g/ml) on the proliferation of Colon 38 cancer cells.
C- control, OD-optical density, X±SEM, *P<0.001 vs C.
Fig. 2.
The effects of various concentrations of proglumide (P) on the proliferation of Colon 38 cancer cells.
C-control, OD-optical density, X±SEM, *P<0.001 vs C, **P<0.01 vs C.
Fig. 3.
The effect of proglumide (P), 5-fluorouracil (FU) and combination of proglumide and 5-fluorouracil in concentration of 2.5 g/ml
on the proliferation of Colon 38 cancer cells.
Cm-control for fluorouracil (with complete medium only), Ce-control forproglumide (complete medium with ethanol), OD-optical density, X±SEM,
*P<0.001 vs Cm, **P<0.05 vs Ce, ***P<0.001 vs Cm and Ce, ^P<0.05 vs FU-2.5, ^^P<0.001 vs FU-2.5,
#P<0.001 vs P-8, ##P<0.001 vs P-9,
###P<0.001 vs P-10, +P<0.01 vs P-8FU and vs P-9FU.
Culture II
0.67
0.68
0.69
0.7
0.71
0.72
0.73
0.74
0.75
0.76
C P-5 P-6 P-7 P-8
OD
Culture III
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Cm Ce FU-2.5 P-8 P-9 P-10 P-8+FU P-9+FU P-10+FU
OD
Culture I
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
C FU-25 FU-2.5 FU-0.25
OD
***
** *
***
^^
###
+
***
^^
##
***
^
#
*****
Fig. 3. Effects of proglumide (P), 
5-fluorouracil (FU) and of the combination 
of proglumide and 5-fluorouracil, in 
concentration of 2.5 µg/ml, on the 
proliferation of Colon 38 cancer cells. 
Cm-control for fluorouracil (with complete 
medium only), Ce-control forproglumide 
(complete medium with ethanol), OD-optical 
density, X±SEM, *P<0.001 vs Cm, **P<0.05 
vs Ce, ***P<0.001 vs Cm and Ce, ^P<0.05 vs 
FU-2.5, ^^P<0.001 vs FU-2.5, #P<0.001 vs 
P-8, ##P<0.001 vs P-9, ###P<0.001 vs P-10, 
+P<0.01 vs P-8FU and vs P-9FU.
Ryc. 3. Wpływ proglumidu (P), 5-fluorouracylu (FU) oraz łącznego zastosowania proglumidu i fluorouracylu w stężeniu 
2,5µg/ml na proliferację komórkową linii Colon 38. Cm-ko trola dla fluorouracylu (medium pełne), Ce-kontrola dla 
proglumidu (medium pełne i etanol), OD-optical density, X±SEM, *P<0,001 vs Cm, **P<0,05 vs Ce, ***P<0,001 vs Cm i 
Ce, ^P<0.05 vs FU-2,5; ^^P<0,001 vs FU-2,5; 
#P<0,001 vs P-8; ##P<0,001 vs P-9; ###P<0,001 vs P-10; +P<0,01 vs P-8FU 
i vs P-9FU.
P
R
A
C
E
  
O
R
Y
G
IN
A
L
N
E
938
8. Monges G, Biagini P, Cantaloube JF. Detection of gastrin 
mRNA in fresh human colonic carcinomas by revers 
transcription – polymerase chain rection. J Mol Endocrinol 
1993; 11(2): 223-9.
9. Smith JP, Stock EA, Woltering MG et al. Characterization of 
the CCK-B/gastrin-like receptor in human colon cancer. Am 
J Physiol 1996; 271: R797-805.
10. Van Solonge WW, Nielsen FC, Friis-Hansen L. Expression 
but incomplete maturation of progastrin in colorectal 
carcinomas. Gastroenterology 1993; 104(4): 1099-1107.
11. Kikendall JW, Glass AR, Sobin LH. Serum gastrin is not 
higher in subjects with colonic carcinoma. Am J Gastroenterol 
1992; 87(10): 1394-1397.
12. Stepan VM, Sawada M, Todisco A, Dickinson CJ. Glycine-
extended gastrin exerts growth promoting effects on human 
colon cancer cells. Mol Med 1999; 5(3): 147-159.
13. Mełeń-Mucha G. The combined effects of tamoxifen or 
proglumide with 5-fluorouracil on the growth of murine 
transplantable Colon 38 cancer. GI Cancer 2001; 3(5): 383-
394.
14. Singh P, Walker JP, Townsend CM, Thompson JC. Role 
of gastrin and gastrin receptors on the growth of a 
transplantable mouse colon carcinoma (MC-26) in BALB/c 
mice. Cancer Res 1986; 46: 1612-1616.
15. Mauss S, Niederau C, Hengels KJ. Effects of gastrin, 
proglumide, loxiglumide and L365, 260 on the growth of 
human colon carcinoma cells. Anticancer Res 1994; 14(1A): 
215-220.
16. Mełeń-Mucha G. Effects of short term treatment with 
pentagastrin, proglumide, tamoxifen given separately or 
together with 5-fluorouracil on the growth in the murine 
transplantable Colon 38 cancer. Neoplasma 2001; 48(2): 134-
139.
17. Thorburn CM, Friedman GD, Dickinson CJ et al. Gastrin 
and colorectal cancer: a prospective study. Gastroenterology 
1998; 115(2): 275-280.
18. Cobb S, Wood T, Ceci J et al. Intestinal expression of mutant 
and wild-type progastrin significantly increases colon 
carcinogenesis in response to azoxymethane in transgenic 
mice. Cancer 2004; 100(6); 1311-23.
19. Cobb S, Wood T, Tessarollo L et al. Deletion of functional 
gastrin gene markedly increases colon carcinogenesis in 
response to azoxymethane in mice. Gastroenterology 2002; 
123(2): 516-30.
20. Singh P, Velasco M, Given R et al. Progastrin expression 
predisposes mice to colon carcinomas and adenomas in 
response to a chemical carcinogen. Gastroenterology 2000; 
119(1): 162-171.
21. Baba M, Itoh K, Tatsuta M. Glycine-extended gastrin induces 
matrix metalloproteinase-1- and –3-mediated invasion of 
human colon cancer cells through type I collagen gel and 
Matrigel. Int J Cancer 2004; 111(1): 23-31.
22. Beauchamp RD, Townsend CM, Singh P et al. Proglumide, a 
gastrin receptor antagonist, inhibits growth of colon cancer 
and enhances survival in mice. Ann Surg 1985; 202: 303-309.
23. Chen D, Destree M, Hakanson R, Willems G. Endogenous 
hypergastrinaemia does not promote growth of colonic 
mucosa or of a transplanted colon adenocarcinoma in rats. 
Eur J Gastroenterol Hepatol 1998; 10(4): 293-299.
24. Niv Y, Heizelracht N, Lamprecht SA et al. Gastrin levels in 
colorectal cancer. Isr J Med Sci 1997; 33(3): 186-9.
25. Bomski G, Gąsiorowska A, Orszulak-Michalak D et al. 
Differences in plasma gastrin, CEA, CA 19-9 concentration 
in patients with proximal and distal colorectal cancer. Int J 
Gastrointest Cancer 2002; 31(1-3): 155-163.
The combine effects of proglumide and fluorouracil on Colon 38 cancer Mełeń-Mucha G.
